Rapid development of a synthetic DNA vaccine for COVID-19

Trevor R.F. Smith; Kate E. Broderick; Jason S. McLellan; Katherine Schultheis; Nicholas J. Tursi; Stephanie Ramos; Miguel Vasquez; Patrick Pezzoli; Laurent Humeau; Susanne N. Walker; Ami B. Patel; Makan Khoshnejad; Igor Maricic; Xizhou Zhu; Timothy A. Herring; David B. Weiner; Alison Generotti; Ami Shah Brown; E. Gary; Kar Muthumani; Kevin Y. Kim; Dinah Amante; Yaya Dia; Daniel Wrapp; J Joseph Kim; Emma L. Reuschel; Yuanhan Wu; Mamadou A. Bah; Daniel W. Kulp; Neethu Chokkalingam; Jean Boyer; Dustin Elwood; Jihae Choi; Jian Yan; Nianshuang Wang; Elizabeth M. Parzych; Faraz I. Zaidi; Ali Raza Ali; Sophia M. Reeder; Daniel Park; Maria Yang; Jewell Walters; Arthur Doan; Jacqueline T. Chu

doi:10.21203/rs.3.rs-16261/v1

Rapid development of a synthetic DNA vaccine for COVID-19

Trevor R.F. Smith(Inovio Pharmaceuticals (United States)), Kate E. Broderick(Inovio Pharmaceuticals (United States)), Jason S. McLellan(The University of Texas at Austin), Katherine Schultheis(Inovio Pharmaceuticals (United States)), Nicholas J. Tursi(The Wistar Institute), Stephanie Ramos(Inovio Pharmaceuticals (United States)), Miguel Vasquez(Inovio Pharmaceuticals (United States)), Patrick Pezzoli(Inovio Pharmaceuticals (United States)), Laurent Humeau(Inovio Pharmaceuticals (United States)), Susanne N. Walker(The Wistar Institute), Ami B. Patel(The Wistar Institute), Makan Khoshnejad(The Wistar Institute), Igor Maricic(Inovio Pharmaceuticals (United States)), Xizhou Zhu(The Wistar Institute), Timothy A. Herring(Inovio Pharmaceuticals (United States)), David B. Weiner(The Wistar Institute), Alison Generotti(Inovio Pharmaceuticals (United States)), Ami Shah Brown(Inovio Pharmaceuticals (United States)), E. Gary(The Wistar Institute), Kar Muthumani(The Wistar Institute), Kevin Y. Kim(The Wistar Institute), Dinah Amante(Inovio Pharmaceuticals (United States)), Yaya Dia(The Wistar Institute), Daniel Wrapp(Duke University), J Joseph Kim(Inovio Pharmaceuticals (United States)), Emma L. Reuschel(The Wistar Institute), Yuanhan Wu(The Wistar Institute), Mamadou A. Bah(The Wistar Institute), Daniel W. Kulp(The Wistar Institute), Neethu Chokkalingam(The Wistar Institute), Jean Boyer(University of Pennsylvania), Dustin Elwood(Inovio Pharmaceuticals (United States)), Jihae Choi(The Wistar Institute), Jian Yan(Inovio Pharmaceuticals (United States)), Nianshuang Wang(The University of Texas at Austin), Elizabeth M. Parzych(The Wistar Institute), Faraz I. Zaidi(The Wistar Institute), Ali Raza Ali(The Wistar Institute), Sophia M. Reeder(The Wistar Institute), Daniel Park(Harvard University), Maria Yang(Inovio Pharmaceuticals (United States)), Jewell Walters(Inovio Pharmaceuticals (United States)), Arthur Doan(Inovio Pharmaceuticals (United States)), Jacqueline T. Chu(Harvard University)

Research Square

March 3, 2020

10.21203/rs.3.rs-16261/v1

Cited by 10

Related Papers

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

|Science|2020|9.8k

Site-specific glycan analysis of the SARS-CoV-2 spike

|Science|2020|1.7k

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

|Nature|2020|1.7k

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

|Science|2020|1.4k

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

|Proceedings of the National Academy of Sciences|2017|1.2k